Overview

Cabozantinib With Topotecan-Cyclophosphamide

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma. - The names of the drugs are: - Cabozantinib - Topotecan - Cyclophosphamide - The names of the non-investigational supportive care drugs are: - Filgrastim, pegfilgrastim, or a related growth factor.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Treatments:
Cyclophosphamide
Mitogens
Topotecan